SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending amid increased discussion of potential collaborations with ExxonMobil on carbon capture technology for data centers, sparked by a recent conference call. The community is focused on interpreting statements made during the call and the potential impact of any partnership on FCEL's future prospects, especially when compared to sector peers. Interest is also fueled by the rising demand for clean energy solutions to power AI.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to a recent volume spike and increased attention on its micro float. Community members are discussing the potential for a significant price increase, drawing comparisons to other low-float stocks that have experienced parabolic runs. The stock's recent price action and the possibility of a squeeze are also key talking points.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending due to the appointment of a new CFO from Johnson & Johnson, sparking optimism about the company's future financial strategies. Community members are actively discussing the potential impact on the company's valuation and long-term prospects, especially with upcoming earnings and existing discussions of Medicare coverage for XPHOZAH.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders assess market volatility amid mixed signals, including concerns about potential pullbacks and upcoming earnings reports from major tech companies. Community discussions revolve around hedging strategies and interpreting market indicators, with some anticipating a possible market correction or a volatility spike due to geopolitical tensions or economic uncertainty. The potential impact of upcoming economic data and policy decisions on market stability is also a key focus.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending after reporting earnings that beat expectations and raising its full-year outlook, triggering multiple analyst upgrades and target price increases. The community is buzzing about the company's growth potential in AI, cybersecurity, and crypto, with some viewing it as a future "magnificent seven" stock. Discussions also highlight Cloudflare's move to enable website owners to monetize AI bot crawler access, sparking debate about the future of content creation and intellectual property.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Recent community discussion around MNKD centers on Oppenheimer's raised price target and speculation regarding a potential deal with Dexcom and pediatric approval for Afrezza. Increased trading volume has some investors suggesting a possible short squeeze. Others express concern about the company's performance and CEO, citing past failures and the need for new catalysts.

Armada Acquisition Corp. II operates as a blank check company. It engages in effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Philadelphia, PA.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Evernorth Holdings Inc. ($XRPN) is trending as the ticker change from $AACI sparks interest and excitement among investors. The community is discussing the relationship with XRP and anticipating potential movement, with some highlighting the upcoming reverse merger expected in Q1 2026.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is trending as the community discusses its technology stack and potential for interoperability solutions within the crypto and traditional finance sectors. Recent developments around tokenization and institutional adoption, including a new ETP, are fueling optimism. Community members are closely watching price movements and anticipating a breakout.

Teucrium Trading, LLC - Teucrium Corn Fund

Teucrium Corn Fund ($CORN) is trending amidst discussions around potential options strategies and LEAPS contracts, with traders exploring opportunities for ROI. Community discussions also highlight factors influencing the broader grain market, including easing trade tensions and reports related to corn and ethanol. Some analysts point to technical indicators and chart patterns, while others monitor weather conditions and USDA reports for potential impacts on yields and prices.

Stem, Inc. engages in the provision of an energy storage system, hardware, ongoing software platform and professional services, and solar asset performance monitoring and control. The company was founded in 2009 and is headquartered in Houston, TX.

Stem Inc - Ordinary Shares - Class A

Stem Inc

Stem Inc. is trending as analysts play catch-up, raising price targets after recent earnings, though still below current trading levels. Community discussions focus on the potential for increased volatility and upcoming resistance points, with some seeing the selloff as overdone due to improved guidance on key metrics. The broader energy storage sector's potential, particularly linked to AI and grid stability, fuels continued interest in the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's  What You Should Know

The consensus price target hints at a 63.6% upside potential for Oruka Therapeutics, Inc. (ORKA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MoonLake Immunotherapeutics shares crashed nearly 90% to record its worst session ever on Monday, as analysts downgraded the stock after the company announced late-stage trial results of its lead drug, sonelokimab, for the treatment of moderate-to-severe hidradenitis suppurativa (HS).By the end of the session, the stock had dropped to $6.25, marking its lowest levels in over three years, before gaining approximately 4.7% in after-hours trading.BTIG downgraded MoonLake to 'Neutral' from 'Buy' and removed the stock from its list of top picks for the second half of the year, saying sonelokimab failed to show differentiation in the Phase 3 VELA-1 and VELA-2 trials. The analyst noted that the placebo-adjusted HiSCR75 results were “well into our worst case scenario” and did not demonstrate a clear efficacy advantage over Bimzelx.Jefferies analyst Clara Dong also downgraded the stock to 'Hold' from 'Buy' and reduced the price target to $8 from $65, citing a smaller commercial opportunity, a lower likelihood of approval despite the drug’s potential path forward, and lesser M&amp;A value.Wolfe Research double-downgraded MoonLake to 'Underperform' from 'Outperform' with a steep price target cut to $2 from $76, saying that even if sonelokimab eventually finds a path forward in HS, realizing stock value “will take too long and will be too tough.”&nbsp;The brokerage firm called the outcome a “surprising MoonLake fiasco,” comparing it to Acelyrin’s collapse after its own HS trial failure, noting that Acelyrin’s stock never rebounded despite later-stage programs in PsA and TED.Leerink Partners highlighted Oruka Therapeutics as a likely beneficiary, noting that its drug, ORKA-002, with a mechanism similar to Bimzelx, could gain traction following MoonLake’s results.&nbsp;On Stocktwits, retail sentiment for MoonLake was ‘extremely bullish’ amid a 4,650% surge in 24-hour message volume.One user expressed confidence in MoonLake’s leadership and long-term outlook, stating that the company has a strong management team and a promising future, with potential for eventual FDA approval.<stembedurl>https://stocktwits.com/HitNRun79/message/630422460</stembedurl>Another user noted that the trial results, while not ideal, still showed meaningful efficacy. They suggested that the sharp decline in the stock was driven more by fear and short-seller activity than by fundamentals, and added that they had taken a position in the stock following the selloff.<stembedurl>https://stocktwits.com/freshstart2021/message/630421221</stembedurl><a href="https://stocktwits.com/symbol/MLTX">MoonLake’s stock</a> has declined 88.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades

Wolfe Research compared MoonLake’s setback to Acelyrin’s HS trial failure, noting that Acelyrin’s stock never rebounded despite later progress in other programs.

Equity

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.58	--	--	N/A
Q2 '25	-$0.49	-$0.46	6.14%	BEAT
Q1 '25	-$0.51	-$0.40	21.31%	BEAT
Q4 '24	-$0.74	-$0.49	34.12%	BEAT
Q3 '24	-$0.40	-$1.46	-263.27%	MISSED

ORKA
Oruka Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ORKA News

ORKAOruka Therapeutics Inc.